Merck KGaA's potential acquisition of SpringWorks Therapeutics ($SWTX) remains uncertain as the company has not confirmed any developments regarding the deal. Following Merck's recent earnings report, speculation continues about whether an acquisition will occur, with various analysts expressing mixed opinions. Some suggest that discussions may still be ongoing, while others express skepticism about the likelihood of the deal materializing. Merck KGaA has indicated that its primary focus in mergers and acquisitions is on Life Sciences rather than healthcare, although it is open to healthcare acquisitions if they can be adequately derisked. Market activity around $SWTX options suggests traders are anticipating potential developments in the coming weeks, with notable volume in calls for March 21st. As investors and oncology experts closely monitor the situation, Merck remains tight-lipped about its negotiations.